Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status
Publication
, Conference
Rich, J; Shi, Q; Hjelmeland, M; Goudar, R; Keir, S; McLendon, R; Reese, E; Traxler, P; Lane, H; Bigner, D; Friedman, H
Published in: NEURO-ONCOLOGY
July 1, 2005
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
343 / 344
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Rich, J., Shi, Q., Hjelmeland, M., Goudar, R., Keir, S., McLendon, R., … Friedman, H. (2005). Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status. In NEURO-ONCOLOGY (Vol. 7, pp. 343–344). Edinburgh, SCOTLAND: DUKE UNIV PRESS.
Rich, J., Q. Shi, M. Hjelmeland, R. Goudar, S. Keir, R. McLendon, E. Reese, et al. “Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status.” In NEURO-ONCOLOGY, 7:343–44. DUKE UNIV PRESS, 2005.
Rich J, Shi Q, Hjelmeland M, Goudar R, Keir S, McLendon R, et al. Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 343–4.
Rich, J., et al. “Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status.” NEURO-ONCOLOGY, vol. 7, no. 3, DUKE UNIV PRESS, 2005, pp. 343–44.
Rich J, Shi Q, Hjelmeland M, Goudar R, Keir S, McLendon R, Reese E, Traxler P, Lane H, Bigner D, Friedman H. Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2005. p. 343–344.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
July 1, 2005
Volume
7
Issue
3
Start / End Page
343 / 344
Location
Edinburgh, SCOTLAND
Publisher
DUKE UNIV PRESS
Conference Name
2nd Quadrennial Meeting of the World-Federation-of-Neuro-Oncology/6th Meeting of the European-Association-for-Neur-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences